KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Abbott Laboratories (ABT) over the last 17 years, with Q3 2025 value amounting to -$90.0 million.

  • Abbott Laboratories' Gains from Investment Securities fell 32500.0% to -$90.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 billion, marking a year-over-year increase of 1864.88%. This contributed to the annual value of $1.7 billion for FY2024, which is 1681.36% up from last year.
  • As of Q3 2025, Abbott Laboratories' Gains from Investment Securities stood at -$90.0 million, which was down 32500.0% from $52.0 million recorded in Q2 2025.
  • In the past 5 years, Abbott Laboratories' Gains from Investment Securities registered a high of $1.9 billion during Q4 2021, and its lowest value of -$90.0 million during Q3 2025.
  • For the 5-year period, Abbott Laboratories' Gains from Investment Securities averaged around $376.1 million, with its median value being $40.0 million (2024).
  • In the last 5 years, Abbott Laboratories' Gains from Investment Securities soared by 85000.0% in 2023 and then crashed by 32500.0% in 2025.
  • Quarter analysis of 5 years shows Abbott Laboratories' Gains from Investment Securities stood at $1.9 billion in 2021, then fell by 1.88% to $1.9 billion in 2022, then decreased by 23.86% to $1.4 billion in 2023, then grew by 21.12% to $1.7 billion in 2024, then tumbled by 105.2% to -$90.0 million in 2025.
  • Its Gains from Investment Securities stands at -$90.0 million for Q3 2025, versus $52.0 million for Q2 2025 and -$8.0 million for Q1 2025.